Seres And Ferring Go Head-To-Head In Recurrent C. Difficile Market

Two New Microbiome Medicines Launched In 2023

 
• By David Wild
Patients with recurrent C. difficile now have two comparable treatments • Source: Shutterstock

More from Market Access

More from In Vivo